AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21882997
Drug: Internet-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based behavioral weight loss program with weekly group meetings delivered entirely by online synchronous chats
Trial: 21882997
Drug: Internet-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based behavioral weight loss program with weekly group meetings delivered by a combination of online chats plus monthly in-person group sessions
Trial: 17022844
Drug: Ropinirole 0.25‐4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole 0.25‐4.0 mg once daily 1‐3 hours before bedtime
Trial: 9114180
Drug: Sequential episodes
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential episodes of C. difficile diarrhea
Trial: 1549227
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (average doses: 5 to 10, 10 to 20, and 20 to 40 units per muscle)
Trial: 31179007
Drug: 3-day placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day placebo treatment
Trial: 22508360
Drug: 25% (w/v)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% (w/v) honey solution
Trial: 18005909
Drug: EPs (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPs (30 drops, 1.5 mL, three times a day for a maximum of 10 days)
Trial: 9563220
Drug: metronidazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metronidazole (400 mg t.i.d. for 7 days)
Trial: 9563220
Drug: secnidazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secnidazole (500 mg t.i.d. for 5 days)
Trial: 7996065
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose steroids
Trial: 29778364
Drug: Cilostazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (100 mg twice a day)
Trial: 29778364
Drug: Cilostazol plus
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol plus probucol (250 mg twice a day)
Trial: 29778364
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus probucol
Trial: 28142074
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT) treatment on scan 2
Trial: 28142074
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT) treatment
Trial: 26226536
Drug: Proactive QL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive QL intervention with up to an 8-week supply of free nicotine replacement therapy
Trial: 26226536
Drug: Reactive QL
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive QL intervention with a 2-week supply of nicotine replacement therapy
Trial: 17044457
Drug: Tacrolimus +
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus + Fluconazole (100-200 mg/day for one week)
Trial: 17044457
Drug: Tacrolimus (stable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (stable dosage)
Trial: 8638341
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for seven days postoperatively
Trial: 8638341
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no NSAID treatment)
Trial: 6223651
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol solution
Trial: 25057105
Drug: 5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/day of Arthrospira platensis (Asp)
Trial: 23083772
Drug: AMG 145
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 145 (doses of 7, 21, 70, 210, or 420 mg SC; 21 or 420 mg IV; 14 or 35 mg QW ×6; 140 or 280 mg Q2W ×3; 420 mg every 4 weeks ×2)
Trial: 23083772
Drug: AMG 145
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 145 (140 mg Q2W ×3)
Trial: 20179322
Drug: C.E.R.A. administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.E.R.A. administered via intravenous (IV) route once every 2 weeks (Q2W)
Trial: 20179322
Drug: C.E.R.A. administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.E.R.A. administered via subcutaneous (SC) route once every 4 weeks (Q4W)
Trial: 20179322
Drug: C.E.R.A. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.E.R.A. administration (IV or SC)
Trial: 20179322
Drug: Dosing schedule,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing schedule, administration route, and study type
Trial: 18990320
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of DHEA daily for 12 weeks
Trial: 15931623
Drug: Intravenous cyanocobalamin
RxNorm normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cyanocobalamin every 14 days
Trial: 15931623
Drug: Intravenous cyanocobalamin
RxNorm normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cyanocobalamin every 7 days
Trial: 15931623
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1 mg intravenous cyanocobalamin every 28 days)
Trial: 12939214
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a prothrombotic risk factor with an underlying condition
Trial: 9179835
Drug: Decision support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision support using the hand-held patient-oriented insulin regimen optimizer (POIRO)
Trial: 6367528
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (AMCA) 1 g t.i.d. 24 h prior to and following intradermal injection of anti-IgE
Trial: 23010094
Drug: 17 alpha-hydroxyprogesterone
RxNorm normalized name: 17 alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-hydroxyprogesterone caproate (250 mg, weekly intramuscular)
Trial: 18707726
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice cocktail (3 times daily)
Trial: 18707726
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (multiple daily dosing)
Trial: 10573193
Drug: Clomipramine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine at 0.5 to 1.0 mg/kg twice daily
Trial: 10573193
Drug: Clomipramine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine at 1.0 to 2.0 mg/kg twice daily
Trial: 8916636
Drug: Participants whose
RxNorm normalized name: Allium fistulosum whoe extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants whose depression symptoms decreased from baseline to the end of treatment
Trial: 8916636
Drug: Participants whose
RxNorm normalized name: Allium fistulosum whoe extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants whose depression symptoms increased from baseline to the end of treatment
Trial: 6218577
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard antimicrobial therapy)
Trial: 31806944
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT) with 2000 pulses; 2.5 bars; 5 Hz, 7 mins, performed twice a week for five weeks (10 sessions) and stabilization training
Trial: 31806944
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT) with stabilization training
Trial: 19632665
Drug: 10 units
RxNorm normalized name: Omnipod GO 10 Units/Day Pods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 units of intramuscular oxytocin (group 1)
Trial: 19632665
Drug: 600 microg
RxNorm normalized name: Fentanyl 600 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 microg oral misoprostol (group 2)
Trial: 19632665
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional medication (group 3)
Trial: 17020910
Drug: High-dose diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose diazepam (15 mg)
Trial: 17020910
Drug: Low-dose diazepam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose diazepam (5 mg)
Trial: 9394987
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of gold sodium thiomalate
Trial: 3368545
Drug: Low-dose neuroleptics
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose neuroleptics
Trial: 3368545
Drug: Low-dose neuroleptics
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose neuroleptics (excluding relapsed patients)
Trial: 20631375
Drug: Romiplostim 750
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Romiplostim 750 μg
Trial: 21519749
Drug: Flaxseed powder
RxNorm normalized name: Flaxseed Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed powder (60 g/day, 10 g ALA)
Trial: 21519749
Drug: Isocaloric roasted
RxNorm normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric roasted cassava powder (60 g/day, fat-free)
Trial: 7691775
Drug: Grid laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grid laser treatment (low energy scatter photocoagulation applied to areas of presumed CNV and abnormal retinal pigment epithelium, sparing the fovea)
Trial: 7691775
Drug: Grid laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grid laser treatment and Natural course (control group)
Trial: 27941937
Drug: Pegylated-interferon-alpha-2b monotherapy
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegylated-interferon-alpha-2b monotherapy or combination therapy with adefovir dipivoxil
Trial: 24323035
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/d continuously plus prednisone 5 mg twice daily
Trial: 12860491
Drug: Simvastatin (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40-80 mg)
Trial: 12860491
Drug: Atorvastatin (20-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20-80 mg)
Trial: 8905602
Drug: Oral oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestradiol
Trial: 7506866
Drug: Cefotiam 4
RxNorm normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotiam 4 g a day for 7 days (arm A)
Trial: 7506866
Drug: Tosufloxacin 300
RxNorm normalized name: tosufloxacin
DrugBank: Tosufloxacin (DB16850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tosufloxacin 300 mg a day for 7 days (arm B)
Trial: 19824561
Drug: G-Bond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Bond
Trial: 20463100
Drug: Calcium load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium load (600 mg of calcium carbonate)
Trial: 12816288
Drug: Guided tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided tissue regeneration (GTR) with anti-infective therapy (metronidazole gel, chlorhexidine gluconate 0.2%, doxycycline 100 mg x 1/day for 6 to 8 weeks, ibuprofen 3 x 400 mg/day for 7 days)
Trial: 12816288
Drug: Guided tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided tissue regeneration (GTR) without anti-infective therapy (chlorhexidine gluconate 0.2% for 1 week, doxycycline 100 mg x 1/day for 1 week, ibuprofen 3 x 400 mg/day for 7 days)
Trial: 10519578
Drug: Intracameral 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral 1% unpreserved lidocaine combined with topical anesthesia (oxybuprocaine)
Trial: 10519578
Drug: Peribulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar anesthesia with 6 ml prilocaine
Trial: 2477130
Drug: Cibenzoline (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (130 to 160 mg bid)
Trial: 2477130
Drug: Cibenzoline (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (130 to 160 mg bid) in phase 2
Trial: 30571546
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17β‐estradiol per day
Trial: 30571546
Drug: 2+2 mg
RxNorm normalized name: siponimod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2+2 mg 17β‐estradiol per day
Trial: 21709093
Drug: Finafloxacin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finafloxacin (up to 800 mg)
Trial: 21709093
Drug: Finafloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finafloxacin (400 mg and above)
Trial: 15329112
Drug: sustained-release alfuzosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release alfuzosin 5 mg twice daily
Trial: 9333329
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch 10% (200/0.5) at 12 ml per kg body-weight daily
Trial: 28058714
Drug: Myo‐inositol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo‐inositol 1000 mg, Tribulus Terrestris 300 mg, Alga Ecklonia Bicyclis 200 mg and Biovis one tablet a day for 90 days
Trial: 28058714
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet a day for 90 days
Trial: 24490577
Drug: Jiangzhikangyanghua mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiangzhikangyanghua mixture 20 mL tid + amlodipine 5 mg qd + valsartan 80 mg qd
Trial: 24490577
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg qd + valsartan 80 mg qd
Trial: 21328025
Drug: G-CSF (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (1.5 μg/kg) injected for 14 consecutive days
Trial: 10999555
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 300 mg/d
Trial: 30656993
Drug: Paracetamol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1 g every 6 hours)
Trial: 25251999
Drug: Lipegfilgrastim 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipegfilgrastim 25 µg/kg (body-weight-adjusted)
Trial: 25251999
Drug: Lipegfilgrastim 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipegfilgrastim 50 or 100 μg/kg
Trial: 25251999
Drug: Lipegfilgrastim 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipegfilgrastim 6 mg (fixed-dose)
Trial: 25251999
Drug: Pegfilgrastim 100
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim 100 μg/kg
Trial: 25251999
Drug: Pegfilgrastim 6
RxNorm normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim 6 mg (fixed-dose)
Trial: 21675542
Drug: Emotion-focused self-regulation
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion-focused self-regulation strategies (e.g., comfort seeking)
Trial: 21675542
Drug: Planful self-regulation
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Planful self-regulation strategies (e.g., distraction)
Trial: 19532850
Drug: Tramadol/acetaminophen and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/acetaminophen and naloxone infusion (0.25 microg/kg/h for 48 hours)
Trial: 19532850
Drug: Tramadol/acetaminophen and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/acetaminophen and naloxone infusion
Trial: 19532850
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (historical controls)
Trial: 16765847
Drug: Sesame oil
RxNorm normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesame oil (SO) 5 ml by mouth at bedtime
Trial: 16765847
Drug: Placebo 5
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5 ml by mouth at bedtime
Trial: 15325416
Drug: Caffeine 3
RxNorm normalized name: caffeine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 3 mg/kg body weight
Trial: 15325416
Drug: Caffeine 5
RxNorm normalized name: caffeine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 5 mg/kg body weight
Trial: 9257377
Drug: Topical retinol
RxNorm normalized name: retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical retinol preparation
Trial: 9257377
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E cream
Trial: 8382234
Drug: Amlodipine (231
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (231 patients, 5-10 mg/day)
Trial: 8382234
Drug: Enalapril (230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (230 patients, 10-40 mg/day)
Trial: 3791659
Drug: Ethanol ingestion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol ingestion (1.5 ml/kg initial dose, maintained at 110-140 mg%)
Trial: 31898656
Drug: Interdigitated HDRICBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdigitated HDRICBT with EBRT 50 Gy/25 fractions and 8 Gy/fraction weekly for three fractions
Trial: 31898656
Drug: Sequential HDRICBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential HDRICBT with EBRT 50 Gy/25 fractions and 8 Gy/fraction weekly for three fractions
Trial: 23136031
Drug: Lowered dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowered dialysate sodium concentration from 140 mmol/l to 138 mmol/l
Trial: 21640057
Drug: Traditional visual/tactile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional visual/tactile oral examination
Trial: 19996424
Drug: Chlorproguanil-dapsone-artesunate (CDA)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chlorproguanil-dapsone-artesunate (CDA) 2.0/2.5/4.0 mg/kg, once daily for 3 days
Trial: 19996424
Drug: Chlorproguanil-dapsone (CPG-DDS)
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorproguanil-dapsone (CPG-DDS) 2.0/2.5 mg/kg, once daily for 3 days
Trial: 11333852
Drug: Home-based dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based dietary treatment with locally available foods and micronutrient supplements
Trial: 9005975
Drug: Hexarelin (HEX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexarelin (HEX) combined with pyridostigmine (PD) 120 mg orally
Trial: 8504051
Drug: 15 micrograms/g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 micrograms/g calcitriol ointment applied twice daily
Trial: 29479099
Drug: Routine periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine periodontal treatment methods for streptococcal gingivitis
Trial: 29479099
Drug: Supportive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive treatment with antacid chewing tablet two times a day for a week
Trial: 16352688
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg daily for 2 months
Trial: 9058444
Drug: Modified Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Group (MG, n = 22)
Trial: 8436149
Drug: Bisoprolol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 2.5 mg per day
Trial: 8436149
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 mg per day
Trial: 2936370
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol (10 mg)
Trial: 2936370
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol (0.6 mg)
Trial: 2936370
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nebulized salbutamol and ipratropium bromide
Trial: 28008244
Drug: Indacaterol/glycopyrronium (IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110 μg/50 μg
Trial: 28008244
Drug: Salmeterol/fluticasone (SFC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone (SFC) 50 μg/500 μg